SanReno Therapeutics
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SanReno Therapeutics
Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV
Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.
BeiGene, CANbridge, Dizal IPOs Set China Biotech Fundraising Record But Share Prices Disappoint
BeiGene’s $3.5bn Shanghai IPO and CANbridge’s Hong Kong listing, as well as Dizal’s offering on the STAR market and five financing rounds totaling $508.5m help set a record for Chinese biotech fundraising in the last month of 2021.
Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals